Please assess the completion status of the following clinical trial:

Trial Title: MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient with histologically proven, measurable metastatic cutaneous melanoma, and with documented progressive disease within the 12 weeks before the first administration of study treatment.~* Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.~* Patient is \>= 18 years of age at the time of signature of the informed consent.~* The patient's tumor shows expression of MAGE-A3 gene~* ECOG performance status of 0 or 1.~* The patient has normal organ functions~* If the patient is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after completion of the injection series.~* In the view of the investigator, the patient can and will comply with the requirements of the protocol.~Exclusion Criteria:~* The patient has at any time received systemic (bio-)chemotherapy (except for isolated limb perfusion, as long as this was performed at least 4 weeks before first study treatment administration).~* The patient is scheduled to receive any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy and immunomodulating agents.~* The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.~* The patient received any cancer immunotherapeutic containing a MAGE-A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.~* The patient has received any investigational or non-registered drug or vaccine other than the study medication within the 30 days preceding the first ASCI injection or it is planned that (s)he will receive such a drug during the study period.~* The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.~* History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.~* The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.~* The patient has a family history of congenital or hereditary immunodeficiency.~* The patient is known to be positive for the Human Immunodeficiency Virus (HIV).~* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.~* The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.~* For female patients: the patient is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1203486A Group (Type: EXPERIMENTAL): Patients received 4 cycles of MAGE-A3 product as follows:~* Cycle 1: 6 doses, each given at a 2-week interval,~* Cycle 2: 6 doses, each given at a 3-week interval~* Cycle 3: 4 doses, each given at a 6-week interval~* Cycle 4: 4 doses, each given at a 3-month interval followed by 4 doses, each given at a 6-month interval.~The MAGE-A3 product was administered intramuscularly in the deltoid or lateral regions of the thighs, alternately on the right and left sides.

Based on this trial design, predict the completion outcome and termination type (if applicable).